Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy

Figure 1. Overall study design diagram. Abbreviation: HIRD, HealthCore Integrated Research Database.

Figure 2. All-cause health care resource utilizationa between adherent and nonadherent patients using PDC calculated from claims for the 12-month period including and after the initial survey. Notes: aUnadjusted results; *p<0.05; PDCAdherent n=323, PDCNonadherent n=352. Abbreviations: PDC, proportion of days covered; INP, inpatient; ER, emergency room.

Figure 3. All-cause health care resource utilizationa between adherent and nonadherent patients using mean MMAS-8 scores determined from patient self-report for the 12-month period including and after the initial survey. Notes: aUnadjusted results; *p<0.05; MMASAdherent n=251, MMASNonadherent n=424. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, USA. Abbreviations: MMAS-8, Morisky Medication Adherence Scale 8-item; INP, inpatient; ER, emergency room.

Figure 4. Comparison of all-cause, stroke-related, and bleeding-related total medical costsa between adherent and nonadherent patients using PDC calculated from claims for the 12-month period including and after the initial survey. Notes: aUnadjusted results; *p<0.05; PDCAdherent n=323, PDCNonadherent n=352. Abbreviation: PDC, proportion of days covered.

Figure 5. Comparison of all-cause, stroke-related, and bleeding-related total medical costsa between adherent and nonadherent patients using mean MMAS-8 scores determined from patient self-report for the 12-month period including and following the initial survey. Notes: aUnadjusted results; MMASAdherent n=251, MMASNonadherent n=424. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, USA. Abbreviation: MMAS-8, Morisky Medication Adherence Scale 8-item.

Figure 6. Comparison of all-cause total medical costs by type of services between adherent and nonadherent patients using PDC and mean overall MMAS-8 scores for the 12-month period including and following the initial survey. Notes: *p<0.05 vs nonadherent PDC cohort; PDCAdherent n=323, PDCNonadherent n=352, MMASAdherent n=251, MMASNonadherent n=424. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, USA. Abbreviations: PDC, proportion of days covered; MMAS-8, Morisky Medication Adherence Scale 8-item.

Figure 7. Comparison of Duke Anticoagulation Satisfaction Scale (DASS) mean scores between adherent and nonadherent patients using PDC and mean overall MMAS-8 scores for the 12-month period including and following the initial survey. Notes: *p<0.05 vs MMAS nonadherent cohort; PDCAdherent n=323, PDCNonadherent n=352, MMASAdherent n=251, MMASNonadherent n=424. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, USA. Abbreviations: PDC, proportion of days covered; MMAS-8, Morisky Medication Adherence Scale 8-item.